EUCTR2004-004596-11-IT进行中（未招募）不适用
Phase II study of VELCADDE in patients with extranodal marginal zone B-cell lymphoma of MALT type pretreated with more than one prior systemiuc therapy regimen
INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)0 个研究点目标入组 28 人开始时间: 2007年8月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Phase II study of VELCADE in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with one prior systemic therapy regimetreatment of extranodal marginal zone B-cell non Hodgkin lymphoma of MALT type with bortezomibMedDRA version: 14.1Level: PTClassification code 10015823Term: Extranodal marginal zone B-cell lymphoma (MALT type) recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-004594-29-ITINTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)35
进行中（未招募）
不适用
Phase II Study of VELCADETM in patientswith extranodal marginal zone B-cell lymphoma ofMALT-type pretreated with more than one prior systemictherapy regimen (X05142)lymphoma of MALTEUCTR2004-004596-11-ESInternational Extranodal Lymphoma Study Group35
进行中（未招募）
1 期
Phase II Study of VELCADETM in patientswith extranodal marginal zone B-cell lymphoma ofMALT-type pretreated with one prior systemic therapyregimen (X05142)EUCTR2004-004594-29-ESInternational Extranodal Lymphoma Study Group35
进行中（未招募）
1 期
A Phase 2 Study of VELCADE™ in Subjects with Relapsed or Refractory follicular B-cell LymphomaFollicular LymphomaEUCTR2005-000734-21-BEGroupe d'Etude des Lymphomes de l'Adulte (GELA)
进行中（未招募）
不适用
A Multicenter, Open-label, Phase 2 Study of VELCADE bortezomib for Injection in Previously treated Patients with Stage IIIB an IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloalveolar FeaturesEUCTR2004-004648-29-ITJANSSEN-CILAG135